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Stavropoula Tjoumakaris, MD; David Hasan, MD; Gorge Eller, MD; David Stidd
MD, Robert H. Rosenwasser, MD, MBA, FACS, FAHA; Pascal Jabbour, MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA

ABSTRACT
Background: Despite the routine clopidogrel/aspirin anti-platelet therapy, complications like thromboembolism, continue to be encountered with PED. We studied the
safety and the efficacy of prasugrel in the management of clopidogrel non-responders
treated for intracranial aneurysms.
Methods: 437 consecutive neurosurgery patients were identified between January 2011
and May 2016. Patients allergic or having <30% platelet-inhibition with a daily 75mg of
clopidogrel were dispensed 10mg of prasugrel daily (n=20) or 90mg of ticagrelor twice
daily (n=2). The average follow-up was 15.8 months (SD=12.4 months). Patient clinical
well being was evaluated with the modified Rankin Scale (mRS) registered before the
discharge and at each follow-up visit. To control confounding we used multivariable
mixed-effects logistic regression and propensity score conditioning.
Results: 26 of 437(5.9%) patients (mean of age 56.3 years; 62 women [14,2%]) presented
with a sub-arachnoid hemorrhage. 1 patient was allergic to clopidogrel and prasugrel
simultaneously. All the patients receiving prasugrel (n=22) had a mRS<2 on their latest
follow-up visit (mean=0.67; SD=1.15). In a multivariate analysis, clopidogrel did not
affect the mRS on last follow-up, p=0.14. Multivariable logistic regression showed that
clopidogrel was not associated with an increased long-term recurrence rate (odds
ratio[OR], 0.17; 95%Confidence Interval [CI95%], 0.01-2.70; p=0.21) neither with an
increased thromboembolic accident rate (OR, 0.46; CI95%, 0.12-1.67; p=0.36) nor
with an increased hemorrhagic event rate (OR, 0.39; CI95%,0.91-1.64; p=0.20). None
of the patients receiving prasugrel deceased or had a long-term recurrence nor a
hemorrhagic event, only 1 patient suffered from mild aphasia subsequent to a thromboembolic event. 3 patients on clopidogrel passed during the study: (2) from acute SAH
and (1) from intra-parenchymal hemorrhage. Clopidogrel was not associated with an
increased mortality rate (OR, 2.18; CI95%,0.11-43.27; p=0.61). The same associations
were present in propensity score adjusted models.
Conclusion: In a cohort of patients treated with PED for their intracranial aneurysms, prasugrel (10mg/day) is a safe alternative to clopidogrel resistant, allergic or
non-responders.
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INTRODUCTION
Since the 2011 FDA approval, PED
has been a favored option in treating
cerebral aneurysm(s). 15 The PED is a
self-expanding stent with 30-35% metal
surface area coverage that diverts blood
flow from the aneurysm lumen to the
downstream arteries causing aneurysm
sac thrombosis. 3 However, there is a
window period until full luminal endothelialization of the PED occurs, during
which the patient is at a high risk of
thromboembolic events.11 2,13 The use of
Dual Anti-Platelet Therapy (DAPT) with
aspirin and clopidogrel has been recommended for preventing thrombotic
and hemorrhagic complications that
occur after the deployment of PEDs.12
However, Delgado Almandoz JE et al.
demonstrated that thromboembolic
complications continue to be encountered, particularly with PED, despite
the routine DAPT. Approximately 30%
of patients exhibit anti-platelet resistance. 1 Insufficient platelet inhibition
in CYP2C19 heterozygotes causes this
variability in the response to clopidogrel.
Several centers have replaced clopidogrel with different anti-aggregation
drugs like prasugrel or ticagrelor in the
management of these resistant cases.5,14
Prasugrel and Ticagrelor achieve more
potent and rapid inhibition of platelet
aggregation and decreased intersubject response variability.6,8 In our
Study, we identified all the patients
that were resistant to clopidogrel. They
were dispensed prasugrel or ticagrelor
in order to achieve the optimal platelet
inhibition. This allowed them to undertake their flow diverting stent treatment.
We demonstrate the safety and efficacy
of prasugrel and ticagrelor as alternative
antiplatelet agents whilst dispensed in
conjunction with aspirin in clopidogrel
non-responders.
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Table 1. Association between outcomes and clopidogrel
Model

Long-term
recurrence

Intra-PED stenosis

Thromboembolic
Complications

Hemorrhagic
Complications

Mortality

OR(CI95%)

p value

OR(CI95%)

p value

OR(CI95%)

p value

OR(CI95%)

p value

OR(CI95%)

p value

Multi-variable
regression

0.17(0.01
to 2.70)

0.21

0.44(0.09 to
2.15)

0.31

0.46(0.12
to 1.67)

0.24

0.39(0.91
to 1.64)

0.20

2.18(0.11
to 43.27)

0.61

Propensity score
adjustment

0.26(0.22
to 3.03)

0.28

0.46(0.09 to
2.44)

0.37

0.39(0.11
to 1.41)

0.82

0.33(0,08
to 1.37)

0.13

0.73(0.75
to 7.17)

0.79

METHODS
Cohort creation
We performed a retrospective cohort
study of all patients undergoing treatment of cerebral aneurysms with flow
diverting stents in a tertiary referral center
between January 2011 and May 2016.
The Institutional Review Board reviewed
and approved the study protocol. All
patients received a pipeline embolization
device (PED; Covidien, Irvine, California).
The characteristics of the cohort at the
baseline can be seen in Table 1.

Treatment protocol
In our institution, patients are pretreated
with 75mg of clopidogrel daily and at least
81mg of aspirin daily for 10 days before
their PED deployment. Some patients
presenting for their intervention without
having received the appropriate 10 days
DAPT were loaded with 325-650mg of
aspirin and a bolus of anti-aggregate
drug (600mg of clopidogrel or 40-60mg
of prasugrel or 90mg of ticagrelor) within
less than 24 hours to their intervention. We routinely calculated the P2Y12
platelet inhibition assay (VerifyNow;
Accumetrics, San Diego, California) for
all the patients before the procedure.
Prasugrel was considered when patients
are allergic, non-responders or resistant
to clopidogrel. Resistance was defined
as having (<30%) of platelets P2Y12
receptor inhibition. 22 patients among
the 437 did not have a significant platelet
inhibition (<30%) with clopidogrel, they
constituted our population. Ticagrelor
was the final alternative for those whose
P2Y12 platelet inhibition was still not
satisfactory with prasugrel. Patients were
continued after the operation on 75mg
of clopidogrel daily or 10mg of prasugrel
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daily or 90mg of Ticagrelor twice daily.
Prophylactic anti-platelets therapy was
given as a minimum of 6 months to 1
year following the procedure.

were reviewed to determine whether
any retroperitoneal, gastrointestinal, or
genitourinary bleeding had occurred.

Exposure variables
Outcome variables
The key primary outcome was the
patients’ Modified Rankin Scale which
was calculated and registered before
the discharge of the patients and at
each follow-up visit. Mortality, thromboembolic events and DSA documented
hemorrhagic accidents, following
the aneurysm’s pipeline treatment,
were considered primary outcomes.
Secondary outcomes were the post
interventional length of stay and the
long-term recurrence.

Patient Follow Up
Patients were scheduled for a follow up
visit with the senior author after 1, 3, 6
and 18 months following their discharge
from the institution.
The efficacy and the safety of the
prophylactic DAPT post pipeline
treatment were evaluated on initial postoperative angiography and follow-up
angiography when available. Cerebrovascular Angiography (digital subtraction
angiography DSA) was required at their
6 months visit and then patients were
followed accordingly to evaluate for
bleeding recurrence or vessel stenosis.
Additional information on the number of
PED used for initial treatment and on the
stent migration were all collected during
the follow up (Table 1). Head computed
tomography scans were compared and
analyzed by the senior author to document any new or recurrent subarachnoid
or intra-parenchymal hemorrhage, only
if the patients were to develop new
insidious symptoms. Medical charts

The primary exposure variable was the
treatment (prasugrel or ticagrelor vs
clopidogrel).
Covariates used for risk adjustment were
age and gender. The comorbidities used
for risk adjustment were: hypertension,
diabetes mellitus, smoking, previous sub
arachnoid hemorrhage, aneurysm size,
per-procedural balloon, previous coiling.

Statistical analysis
To investigate the association of
clopidogrel exposure and our outcome
measures we used several methods to
address confounding. Initially, for binary
outcomes we used a multivariable
logistic regression controlling for all the
covariates mentioned above. In order to
control for clustering at the physician
level, we employed mixed effect models
with physician as a random effects variable. For continuous outcomes, we used
the corresponding linear regression
analyses.
In an alternate way to control for
confounding for binary outcomes we
employed a propensity score adjusted
logistic regression model. To derive the
propensity of receiving clopidogrel we
developed a prediction model using
logistic regression, based on all the
covariates described above. We subsequently employed a logistic regression
with adjustment (stratification) by quantiles (we chose the number of quantiles
to be 10) of the propensity score.
Operating physician was again used as
a random effects variable.
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Table 2. Patient characteristics
Clopidogrel

Prasugrel - Ticagrelor

374

22

Mean

SD

Mean

SD

Age (years)

56.25

13.29

57.31

13.55

Sex

1.15

0.36

1.23

0.43

Hypertension

0.51

0.50

0.54

0.51

Smoking

0.50

0.50

0.65

0.49

Aneurysm size (mm)

9.11

5.87

12.93

10.93

Previous SAH

0.10

0.30

0.15

0.37

Adjunctive Coiling

0.74

0.26

0.08

0.27

Stent migration

0.01

0.09

0.04

0.19

Number of stents per
patient

1.21

0.56

1.32

0.57

mRS on last follow up

0.32

0.75

0.67

1.15

Regression diagnostics were performed
for all analyses. Given that the long-term
recurrence was 2% in a study sample of
437 patients, we had an 80% power to
detect a difference in long-term recurrence as small as 13.4%, at an α-level
of 0.05. All probability values were the
result of two sided tests. Stata version
13 (StataCorp, College Station, TX) was
used for statistical analysis.

RESULTS
Demographic characteristics
Between 2011 and 2016, a total of 437
patients (mean of age 56.3 years; 62
women [14,2%]) underwent treatment
with PED in our institution. 26 (5.9%)
patients presented with an acute subarachnoid hemorrhage (SAH). 374
received clopidogrel [361 with aspirin,
9 with Coumadin, 4 with rivaroxaban],
20 (4.6%; Mean= 0.047; SD= 0.2117)

26

b. Long term recurrence

No

Patients who were lost to follow up were
not included in the original analysis. In
sensitivity analysis, all the above analyses
were repeated used multiple imputations for the patients lost to follow up.
We created 5 imputed datasets. The
directions of the observed associations
did not change and these results are not
reported further.

Published by Jefferson Digital Commons, 2018

JHN JOURNAL

intra-pipeline stenosis (OR, 0.44;
CI95%,0.08 to 2.15; p=0.31). This
was coherent with the propensity
score adjusted model. (OR, 0.46;
CI95%, 0.088 to 2.44; p=0.37).

received prasugrel and 2 received
ticagrelor (Mean=0.0074; SD= 0.0858).
7 patients were lost for follow-up after
their intervention (6 from the clopidogrel
group and 1 from the prasugrel group).
1 patient was reported allergic to clopidogrel and prasugrel. (Table 1)

Efficacy of prasugrel and ticagrelor
a. Intra-pipeline stenosis
Of 369 patients receiving clopidogrel, 23(6.1%) of the patients had an
intra-PED stenosis.
In the group of patients receiving
prasugrel & ticagrelor the mean
of intra-pipeline stenosis was
0.117(SD=0.33), only 2 patients
had an intra-pipeline stenosis:
1(5%) receiving prasugrel the other
ticagrelor. The mean of intra-pipeline stenosis with patients receiving
clopidogrel was 0.071(6.7%;
SD=0.26). A univariate analysis of
the effect of clopidogrel on the
thromboembolic complication
rate did not show any correlation
between the two variables (OR,
0.58; CI95%, 0.12 to 2.70; p=0.48).
In a multivariable mixed-effects
logistic regression, clopidogrel was
not associated with an increased

None of the 22 patients receiving
prasugrel or ticagrelor had a long
term recurrence. Of 374 patients
receiving clopidogrel, 1,6% suffered
from a long term recurrence rate
with a mean of 0.02(SD=0.13). A
univariate analysis of the effect
of clopidogrel on the long term
recurrence rate does not show
any correlation between the two
variables (OR, 0.27; CI95%, 0.03
to 2.41; p=0.24). In a multivariable
mixed-effects logistic regression,
clopidogrel was not associated
with an increased long term recurrence (OR, 0.17; CI95%, 0.01 to
2.70; p=0.21). This was consistent
with the propensity score adjusted
model (OR, 0.26; CI95%, 0.02 to
3.03; p=0.28). (Table.2)

Safety of prasugrel and ticagrelor
c. Post PED complications
Of 22 patients receiving prasugrel
and ticagrelor the mean of postprocedural complications is 0.19
(SD=0.40), only 1 patient developed
an arterio-venous V3 fistula and 1
other patient had an ophtalmoplegia
and a ptosis of the left eye. Of 374
patients receiving Clopidogrel, the
mean post PED complications was
0,53(SD=0.23). A univariate analysis
of the effect of clopidogrel on the
post pipeline complication rate is
associated with an increased post
pipeline complication rate (OR,
0.24; CI95%, 0.08 to 0.70; p=0.01).
In a multivariable mixed-effects
logistic regression, clopidogrel is
also associated with an increased
post pipeline complication rate
(OR, 0.28; CI95%, 0.08 to 1.01;
p=0.05). This was consistent with
the propensity score adjusted model
where p-value was slightly superior
to 0.05 (OR, 0.27; CI95%, 0.07 to
1.03; p=0.055).

3
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Figure 1. Graph showing the mean values of the clinical outcomes according to the prescribed antiplatelet drug

d. Thromboembolic complications
Of 374 patients prescribed clopidogrel, the mean of thromboembolic
events was 0.72(SD=0.26). While 28
(7.4%) patients receiving clopidogrel
had thromboembolic complications,
only 1 patient dispensed prasugrel
suffered from word finding difficulty.
A univariate analysis of the effect of
clopidogrel on the thromboembolic
complication rate does not show any
correlation between the two variables (OR, 0.43; CI95%, 0.14 to 1.32;
p=0.14). We found similar results in
a multivariable mixed-effects logistic
regression (OR, 0.46; CI95%, 0.12 to
1.67; p=0.36) and a propensity score
adjusted model (OR, 0.39; CI95%,
0.11 to 1.41; p=0.82).
e. Hemorrhagic complications
None of the patients receiving
prasugrel or ticagrelor suffered from
hemorrhagic complication. Of 374
patients receiving clopidogrel the
mean of the hemorrhagic complications was 0.45(5.6%; SD=0.21).
A univariate analysis of the effect
of clopidogrel on the hemorrhagic
complication rate does not show
any correlation between the two
variables (OR, 0.36; CI95%, 0.10
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to 1.33; p=0.13). In a multivariable
mixed effect logistic regression,
clopidogrel was not associated with
an increased hemorrhagic event
rate (OR, 0.39; CI95%, 0.91 to 1.64;
p=0.20). We found similar results
with the propensity score adjusted
model (OR, 0.33; CI95%, 0.08 to 1.37;
p=0.13).
f. Mortality
Patients receiving clopidogrel had
a mean mortality rate 0.02(2.67%;
SD=0.15). (Figure.1) 9 patients were
lost: 6 patients dying from various
non PED related events such as
severe sepsis (1), malignant hypertension with large middle cerebral artery
infarct (1), severe gastro-intestinal
complication (1), non reported cause
of death (3). Only 3 patients from this
group were announced dead from
acute SAH (2) and intra-parenchymal
hemorrhage (1). None of the patients
receiving prasugrel and ticagrelor
were lost. A univariate analysis of the
effect of clopidogrel on the mortality
rate does not show any correlation
between the two variables, (OR,
0.61; CI95%, 0.75 to 5.03; p=0.65).
In a multivariable mixed effect
logistic regression, clopidogrel was

not associated with an increased
mortality rate (OR, 2.18; CI95%, 0.11
to 43.27; p=0.61). This persisted in
a propensity score adjusted model
(OR, 0.73; CI95%,0.75 to 7.17; p=0.79).
(Table.2)
g. Latest clinical status
Of 22 patients receiving prasugrel
or ticagrelor, All the patients had a
mRS<=2 on their latest follow-up
visit with a mean of 0.67(SD= 1.15).
98.4% of 374 patients receiving
clopidogrel had a mRS =<2 on their
latest follow-up visit with a mean of
0.32(SD= 0.75). (Figure.1) in a multivariate analysis were the latest mRS
is a dependent variable, clopidogrel
did not affect the mRS score on last
follow-up, p=0.14. (Figure.1)
h. Post interventional hospital stay
Of 22 patients receiving prasugrel
or ticagrelor, the mean of their post
interventional length of stay was 3
days (SD= 6.20). (Figure.1) Of 374
patients receiving clopidogrel the
mean of the post procedural stay
was 1.81 days (SD= 2.67). In a multivariate analysis clopidogrel did not
affect the patients’ post operational
length of stay, p=0.94.
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DISCUSSION
Using a retrospective cohort of candidates with cerebrovascular aneurysm(s),
we did not identify any association
between clopidogrel administration with
mortality, thromboembolic accidents,
long term recurrence, intra-pipeline
stenosis, hemorrhagic events, mRS on
latest follow-up and post operational
hospital length of stay. We found that
clopidogrel is associated with postprocedural complications. Prasugrel
and ticagrelor are increasingly adopted
in clopidogrel resistant individuals
treated for their cerebral aneurysm(s).
Compared to clopidogrel, both prasugrel
and ticagrelor inhibit platelets aggregation more rapidly and consistently with
lower rates of inter-subjects variability.16
In the present study, the efficacy of
prasugrel, depicted by intra-pipeline
stenosis and long-term recurrence, was
roughly similar to clopidogrel (6.1% vs.
5% and 1.6% vs. no recurrence respectively). These results are consistent with
the more favorable pharmacokinetic and
pharmacodynamic profiles of prasugrel,
which affords a more potent and rapid
inhibition of platelet aggregation.1 They
are also in line with the Trial to Assess
Improvement in Therapeutic Outcomes
by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis In Myocardial
Infarction 38 (TRITON-TIMI 38) where
clopidogrel-naïve patients with acute
coronary syndrome scheduled for
percutaneous coronary intervention
on prasugrel therapy showed significantly reduced rates of ischemic events,
including patients with cardiac stent
thrombosis. 17 A recent meta-analysis
done by Patti et al found that switching
from clopidogrel to prasugrel, in patients
undergoing percutaneous coronary
intervention, tended to decrease the
incidence of major adverse cardiac
events during follow-up.9 Despite the
lack of clear evidence supporting its use
in cerebrovascular procedures, LeslieMazwi et al were the first to report the
successful use of prasugrel for acute
in-stent thrombosis in a patient with
reduced clopidogrel response undergoing elective stent-assisted aneurysm
coiling.7
In our series, patients on aspirin and
prasugrel did not have any hemorrhagic
complications. The small number of

28
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patients who were on both aspirin
and prasugrel could explain these
results, as the use of DAPT with aspirin
and prasugrel would be expected to
increase the relative risk of bleeding
by 30% compared to aspirin and clopidogrel. 8,17 Interestingly, the greatest
benefit with prasugrel vs. clopidogrel
in the TRITON-TIMI 38 study was seen
in high-risk patients especially diabetics
or those who suffered an ST-segment
elevation myocardial infarction, where
the major adverse cardiac events’ reduction with prasugrel was not paralleled by
an increased risk of bleeding.9 This may
infer that there are certain subgroups
of patients who are at a decreased risk
of the hemorrhagic adverse events
from prasugrel use. The incidence of
thromboembolic complications was
approximately akin in the aspirin/clopidogrel group (7.4%) and in the aspirin/
prasugrel group (5%). This was not similar
to the extrapolated results of many
studies present in the cardiac literature
that demonstrated superior reduction of
ischemic events using prasugrel as part
of DAPT compared to clopidogrel.10,17
Ticagrelor/aspirin combination was used
only on two patients who either did
not achieve the desired P2Y12 platelet
inhibition with prasugrel or were allergic
to it. One patient had an intra-pipeline
stenosis and another suffered from a
post-procedural hemorrhagic complication manifesting as mild aphasia.
Conclusions about efficacy and safety
of ticagrelor in patients with PED cannot
be drawn from our series because of our
limited number of patients. In their series
of 18 patients, Hanel et al presented their
successful experience with patients
using ticagrelor for different neuroendovascular procedures as an alternative to
clopidogrel in nonresponders.5 Further
investigations in patients undergoing
treatment with PED and other neuroendovascular procedures are needed to
assess the efficacy and safety profile of
ticagrelor in hypo-responders and nonresponders to clopidogrel.
It is noteworthy to state that our series
followed during a mean of 15.8 months
(SD=12.4 months) have showed no
regression but an increasingly improvement of the patients’ clinical wellbeing.
All our patients had a mRS score <=2
and their mean length of stay in the
hospital was approximately 3 days with

65% discharged within two days. This
goes in line with the series of Stetler who
also was able to discharge his patients
on prasugrel on day 1 postoperatively.14
We may reckon that prasugrel would
not only be efficacious, it could be
safe whilst dispensed in this context.
This patient-safety model is definitely
multifactorial and it might not be plainly
related to the use of prasugrel. Although,
we might imply that prasugrel would not
be adversely interfering with the patient’s
clinical wellbeing.
There is still no clear indication for
the use of prasugrel as an alternative
treatment for patients’ resistance to
clopidogrel during the placement of PED.
The main concern of clinicians is the
increased bleeding risks associated with
its use as shown in several cardiovascular
studies.9,17 However, the difference in
end organ result response (brain vs.
cardiac muscle), tortuosity of intracranial vasculature, and amount of metal
implanted make it ineffective to simply
apply cardiac literature to intracranial
procedures.5 Akbari et al 1 presented their
experience with prasugrel and aspirin
in a cohort of 25 patients undergoing
different neuro-endovascular procedures, nine of which undergoing PED
placement. They observed a significant
increase in hemorrhagic complications
(19.4% vs. 3.6%; p=0.02) in the prasugrel/
aspirin group as compared to patients
treated with clopidogrel/aspirin. Jones
et al tried using low dose prasugrel in
two cases following PED implantation
in patients who showed hypo-responsiveness to clopidogrel. Both patients
did well with no thromboembolic or
hemorrhagic complications.6 Our series
of patients treated with PED placement
who were started on prasugrel due to
hypo-responsiveness to clopidogrel is
the largest so far. We did not observe any
ischemic events related to thromboembolism or in-stent thrombosis. We also
did not find an increased risk of bleeding
in those patients. Whether our patients
fall into a subgroup of patients, which
has a lower propensity to have bleeding
complications with prasugrel, or these
results are due to serendipity alone is not
clear. Conclusions cannot be drawn at
this level, and more investigations should
be warranted to study the efficacy and
safety of prasugrel in patients treated
endovascularly with PED placement who

5
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are hypo-responders to clopidogrel.
The higher cost of prasugrel compared
to clopidogrel should be also taken into
consideration when prescribing the
drug.4

4. Gupta R, Moore JM, Griessenauer CJ, Adeeb
N, Patel AS, Youn R, et al: Assessment of
Dual Antiplatelet Regimen for Pipeline
Embolization Device Placement: A Survey of
Major Academic Neurovascular Centers in the
United States. World Neurosurg, 2016

LIMITATIONS

5. Hanel RA: Safety and efficacy of ticagrelor
for neuroendovascular procedures. A
single center initial experience. Journal of
Neurointerventional Surgery, 2014

While our series is one of the largest to
date documenting the safety and efficacy
of prasugrel in the endovascular pipeline
setting, our study design is limited by the
small sample size and by the retrospective nature of data collection. None of
the patients receiving prasugrel manifested major adverse events. This does
not definitively show that prasugrel is as
effective as clopidogrel in the pipeline
patient population and our results could
not be extrapolated to all the neurointervention specialized centers. Further
randomized clinical trials are indispensable to display the promising outcome of
these drugs in what they could replace
clopidogrel in patients receiving PED
flow diversion treatment.

CONCLUSION
The key in assuring clopidogrel resistant
patients long term clinical wellbeing is
by applying the right anti-aggregation
protocol. Approximately 30% of the
patients receiving clopidogrel are
heterozygote for the CYP2C19 gene
and showing a hypo-responsiveness
or resistance (<30% platelet inhibition). Prasugrel is to be considered in
clopidogrel resistant and allergic patients
undergoing flow diversion treatment for
their intracranial aneurysms.
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